Related Experiment Video
Updated: Mar 31, 2026
06:21
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
2.3K
Does Intensive Glucose Control Prevent Cognitive Decline in Diabetes? A Meta-Analysis
Carlos Peñaherrera-Oviedo1, Daniel Moreno-Zambrano1, Michael Palacios1
1Universidad Catolica de Santiago de Guayaquil, 090112 Guayas, Ecuador.
International Journal of Chronic Diseases
|October 15, 2015
Summary
Intensive glucose control in diabetes offers no cognitive benefits for type 1 patients. Type 2 diabetics may see processing speed improvements but risk memory deficits and increased mortality.
Area of Science:
- Endocrinology
- Neurology
- Metabolic Disorders
Background:
- Diabetes mellitus is linked to cognitive decline in both type 1 and type 2 patients.
- Intensive glucose control strategies are debated due to potential mortality risks.
- The impact of treatment intensity on cognitive function requires further investigation.
Purpose of the Study:
- To evaluate the effect of intensive glucose control versus standard therapy on cognitive function in diabetic patients.
- To analyze cognitive performance across different domains and diabetes types.
Main Methods:
- A meta-analysis of 7 studies involving type 1 and type 2 diabetics.
- Inclusion of studies using standardized cognitive function tests.
- Calculation of standardized mean differences (SMDs) for cognitive domains.
Main Results:
- Type 1 diabetics showed no cognitive benefits from intensive glucose control.
- Type 2 diabetics exhibited improvements in processing speed and executive function.
- Type 2 diabetics experienced worse performance in memory and attention domains with intensive control.
- Intensive glucose control was associated with a higher incidence of mortality in type 2 diabetics.
Conclusions:
- Intensive glucose control does not benefit cognitive function in type 1 diabetes.
- For type 2 diabetes, intensive control yields mixed cognitive results and carries increased mortality risks.
- Treatment intensity decisions for diabetes should carefully weigh cognitive and survival outcomes.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
01:22Diabetes Mellitus: Type 2 and Gestational
5.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K
01:22Diabetes Mellitus: Overview and Type I Subtype
6.0K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.0K
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.8K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.8K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
946
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
946